

## The 22nd Biopharmaceutical Forum

**<Enhancing Biopharmaceutical R&D and Quality with Advanced Protein/Peptide Analysis>**

- ◆ Date : 13th (Thu) April, 2017, 09:30~16:00
- ◆ Venue : Seoul COEX Conference Room. 307
- ◆ Program

TIME	TOPIC	SPEAKER
09:30~10:00	<b>Registration</b>	
10:00~10:10	<b>Opening Remarks (KPBMA)</b>	
<b>Session I</b>	<b>Chairman : Dr. So Hun-Young, former Senior Researcher of KRISS (Korea Research Institute of Standards and Science)</b>	
<b>10:10~10:50</b>	Analytical Strategies for Quality Assurance/Quality Control of Biotherapeutic Glycoproteins : Case Study and Practical Guide	Hyun Joo An, Ph.D. Graduate School of Analytical Science and Technology, Asia-Pacific Glycomics Reference Site, Chungnam National University
<b>10:50~11:30</b>	Challenges for Analytical Characterisation of Biopharma products Novel, Biosimilar and Biobetter	Fiona Greer, Ph.D. Global Director, BioPharma Services Development SGS Life Sciences
<b>11:30~12:10</b>	Biosafety Testing : Characterisation of Cell and Virus Banks	Richard Adair, Ph.D. Team leader and Manager, Virology Technical Support Vitrology
<b>12:10~13:30</b>	<b>Lunch &amp; Break</b>	
<b>Session II</b>	<b>Chairman : Dr. Jin Woo Choi, Kyung Hee University College of Pharmacy</b>	
<b>13:30~14:10</b>	Antibody Quality Characterization in Drugs Discovery & Development	Yunfen He, Ph.D. Director of Operations Shanghai OPM Biosciences
<b>14:10~14:50</b>	Introducing the Standardized Quantitative Protocol of Therapeutic Antibody Drugs in Blood and Cell Culture Profiling	Ichiro Hirano Product Manager, Mass Spectrometry Business Unit Shimadzu Corporation, Kyoto, Japan
<b>14:50~15:30</b>	Establishing Biosimilarity : Evaluating Comparability of Primary and Higher Order Biotherapeutic Structure for Candidate Biosimilars	Scott J. Berger, Ph.D. Sr. Manager, Biopharmaceutical Markets Waters Corporation, Milford, MA, USA
<b>15:30~16:00</b>	<b>Q&amp;A &amp; Closing</b>	